Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042104 · ClinicalTrials.gov registry record · NA
EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis
A NA study of Heart Diseases and Aortic Stenosis, Severe, sponsored by Edwards Lifesciences.
- Active
- Registry status
- NA
- Development phase
- 901
- Enrollment target
- 20
- Study locations
NCT03042104 is a NA study of Heart Diseases and Aortic Stenosis, Severe that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 901 participants, below the 5,522-participant average among 85 other Heart Diseases trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT03042104, a NA study of Heart Diseases and Aortic Stenosis, Severe, is active but no longer recruiting, sponsored by Edwards Lifesciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 901 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis.
Conditions Studied
Interventions
- DEVICE Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
Study Locations (20)
California
- Mills Peninsula Health Services - Burlingame
- Cedars-Sinai Medical Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Huntington Hospital - Pasadena
- UC Davis Medical Center - Sacramento
- Kaiser San Francisco Medical Center - San Francisco
- Stanford Hospital and Clinics Palo Alto - Stanford
Illinois
- Northwestern University - Chicago
- Rush University Medical Center Chicago - Chicago
- NorthShore University HealthSystem Research Institution - Evanston
- Alexian Brothers Hospital Network - Lisle
- Prairie Education and Research Cooperative - Springfield
Florida
- The Cardiac & Vascular Institute Research Foundation - Gainesville
- University of Florida - Gainesville
Georgia
- Piedmont Heart Institute - Atlanta
- Emory University - Atlanta
Arizona
- Banner University Medical Center - Phoenix
Colorado
- UC Health Northern Colorado (Medical Center of the Rockies) - Loveland
Connecticut
- Yale University - New Haven
District of Columbia
- Washington Hospital Center DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 901 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2032-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042104
The ClinicalTrials.gov registry entry for NCT03042104 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 901 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,522-participant average among 85 other Heart Diseases trials with a reported enrollment target (84% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which Edwards SAPIEN 3 / SAPIEN 3 Ultra THV is the first listed.
NCT03042104 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT03042104 about?
NCT03042104 is a clinical study titled "EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis". This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis.
What is the current status of trial NCT03042104?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 901 participants. The study started on 2017-07-12. Estimated completion is 2032-03.
What conditions does trial NCT03042104 study?
This clinical trial studies the following conditions: Heart Diseases, Aortic Stenosis, Severe.
What interventions are being tested in trial NCT03042104?
The interventions under investigation include: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV (DEVICE).
Who is sponsoring clinical trial NCT03042104?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03042104 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Angiography and Electrogram Guided Bachmann Bundle Pacing
RECRUITING · NA
-
Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health
RECRUITING · NA
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
RECRUITING · NA
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
RECRUITING · NA
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
RECRUITING · NA
-
Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Failure in the Emergency Department
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.